论文部分内容阅读
目的:观察乳腺浸润性导管癌组织中BRCA1和p120ctn表达及其与临床病理特征之间的关系,探讨它们在乳腺浸润性导管癌发生、发展中的作用及临床应用价值。方法:采用免疫组化方法,检测BRCA1蛋白及p120ctn在乳腺浸润性导管癌、乳腺腺病和癌旁正常组织的表达。分析两者的表达与各病理特征的关系及其两者的相关性。结果:在60例乳腺浸润性导管中,BRCA1蛋白及p120ctn阳性率分别为60.0%(36/60)和35.0%(21/60),分别低于各自在乳腺腺病和癌旁正常组织中的表达(均P<0.05);BRCA1蛋白表达状态与患者高发病年龄、临床病理分期、伴有腋淋巴结转移以及组织学分级有关(均P<0.05),而与肿瘤大小无关(P>0.05);p120ctn表达状态与临床病理分期、伴有腋淋巴结转移以及组织学分级有关(均P<0.05),而与发病年龄、肿瘤大小无关(均P>0.05);BRCA1蛋白与p120ctn在乳腺浸润性导管癌组织中的表达呈正相关(r=0.314,P<0.05)。结论:BRCA1与p120ctn的联合检测可作为乳腺浸润性导管癌诊断、恶性程度及预后判断的指标,为临床个体化治疗提供依据。
OBJECTIVE: To observe the expression of BRCA1 and p120ctn in breast invasive ductal carcinoma and their clinicopathological features, and to explore the role of BRCA1 and p120ctn in the occurrence and development of breast invasive ductal carcinoma and its clinical value. Methods: Immunohistochemistry was used to detect the expression of BRCA1 protein and p120ctn in infiltrating ductal breast, breast adenosis and adjacent normal tissues. Analysis of the relationship between the expression of the two pathological features and the correlation between the two. RESULTS: The positive rates of BRCA1 protein and p120ctn in 60 invasive ductal catheters were 60.0% (36/60) and 35.0% (21/60), respectively, which were lower than those in breast adenosis and adjacent normal tissues (All P <0.05). The expression of BRCA1 protein was correlated with the age of onset, clinical stage, axillary lymph node metastasis and histological grade (all P <0.05), but not with tumor size (P> 0.05). The expression of p120ctn was correlated with clinicopathological stage, axillary lymph node metastasis and histological grade (all P <0.05), but not with age and tumor size (all P> 0.05). The expression of p120ctn in breast invasive ductal carcinoma Tissue expression was positively correlated (r = 0.314, P <0.05). Conclusion: The combined detection of BRCA1 and p120ctn can be used as an index for the diagnosis, malignancy and prognosis of invasive ductal carcinoma of the breast, providing a basis for clinical individualized treatment.